Zoetis Inc. (NYSE:ZTS) Shares Bought by Frank Rimerman Advisors LLC

Frank Rimerman Advisors LLC grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 46,636.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,880 shares of the company’s stock after purchasing an additional 8,861 shares during the period. Frank Rimerman Advisors LLC’s holdings in Zoetis were worth $1,539,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in ZTS. Asset Dedication LLC lifted its holdings in shares of Zoetis by 4.8% during the second quarter. Asset Dedication LLC now owns 1,174 shares of the company’s stock worth $204,000 after purchasing an additional 54 shares during the period. Angeles Wealth Management LLC raised its stake in shares of Zoetis by 3.5% during the 4th quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock valued at $324,000 after buying an additional 56 shares during the last quarter. Forza Wealth Management LLC lifted its holdings in shares of Zoetis by 1.8% in the 2nd quarter. Forza Wealth Management LLC now owns 3,313 shares of the company’s stock valued at $574,000 after buying an additional 58 shares during the period. L. Roy Papp & Associates LLP boosted its stake in shares of Zoetis by 2.8% in the second quarter. L. Roy Papp & Associates LLP now owns 2,221 shares of the company’s stock worth $385,000 after buying an additional 60 shares during the last quarter. Finally, Stokes Family Office LLC grew its holdings in Zoetis by 1.7% during the second quarter. Stokes Family Office LLC now owns 3,826 shares of the company’s stock worth $663,000 after acquiring an additional 65 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 0.3 %

NYSE ZTS opened at $192.64 on Monday. The business has a fifty day moving average price of $184.70 and a 200 day moving average price of $174.33. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The company has a market cap of $87.90 billion, a P/E ratio of 37.12, a P/E/G ratio of 2.98 and a beta of 0.88. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period last year, the firm posted $1.41 earnings per share. Research analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ZTS shares. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Stifel Nicolaus boosted their target price on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Piper Sandler raised their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Finally, BTIG Research upped their price objective on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $220.38.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.